Organogenesis (ORGO) Expected to Announce Earnings on Thursday

Organogenesis (NASDAQ:ORGO) will likely be posting its quarterly earnings results after the market closes on Thursday, February 27th. Analysts expect Organogenesis to post earnings of ($0.03) per share and revenue of $109.60 million for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Organogenesis Trading Down 3.3 %

NASDAQ:ORGO opened at $3.53 on Thursday. Organogenesis has a twelve month low of $2.16 and a twelve month high of $4.57. The company has a market cap of $443.83 million, a P/E ratio of -58.83 and a beta of 1.77. The company has a quick ratio of 2.74, a current ratio of 3.09 and a debt-to-equity ratio of 0.21. The business has a 50 day moving average price of $3.38 and a two-hundred day moving average price of $3.20.

Insider Activity at Organogenesis

In related news, CEO Gary S. Gillheeney sold 41,052 shares of the stock in a transaction on Monday, December 9th. The stock was sold at an average price of $3.52, for a total value of $144,503.04. Following the sale, the chief executive officer now owns 3,359,726 shares in the company, valued at approximately $11,826,235.52. This represents a 1.21 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders have sold 278,116 shares of company stock worth $991,190. Company insiders own 36.90% of the company’s stock.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.